Teva Pharma Industries Ltd ADR (TEVA)

$36.07

up-down-arrow $-0.38 (-1.03%)

As on 31-Aug-2026 15:44EDT

Market cap

info icon

$42,895 Mln

Revenue (TTM)

info icon

$17,314 Mln

P/E Ratio

info icon

62.4

P/B Ratio

info icon

5.6

Div. Yield

info icon

0 %

Teva Pharma Industries Ltd ADR (TEVA) Share Price

Compare

High: Low: Return:

Max: Min: Median:

Max: Min: Median:

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 35.62 High: 36.33

52 Week Range

Low: 18.14 High: 38.37

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    0.1 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    37.32

  • EV/EBITDAEV/EBITDA information

    21.9

  • Debt to EquityDebt to Equity information

    1.6

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $0.6

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    1,165,296,084

10 Years Aggregate

CFO

$27,357.00 Mln

EBITDA

$39,495.00 Mln

Net Profit

$-20,927.00 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Teva Pharma Industries Ltd ADR (TEVA)
15.6 1.8 2.1 96.2 55.0 30.9 -3.3
BSE Sensex
-9.1 -1.2 2.9 -3.6 5.7 6.2 10.5
S&P Midcap 400
12.3 0.7 0.9 15.6 12.4 6.4 9.1
As on 31-Aug-2026
Company
2025
2024
2023
2022
2021
2020
2019
Teva Pharma Industries Ltd ADR (TEVA)
41.6 109.8 14.5 13.9 -17.0 -1.5 -36.4
S&P Midcap 400
5.9 12.1 14.4 -14.5 23.2 11.8 24.1
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Teva Pharma Industries Ltd ADR (TEVA)
36.1 42,894.6 17,314.0 706.0 9.3 9 62.4 5.6
258.1 462,684.3 64,386.0 6,314.0 20.7 -- 75.2 50.5
430.2 233,780.1 38,125.0 8,743.0 25.0 85.9 26.9 20.2
1,161.3 1,109,683.0 79,665.8 26,709.5 31.2 88.4 42.9 33.7
146.4 180,636.7 30,456.0 -3,240.0 29.7 -18.8 17.7 15.6
266.6 644,334.6 97,929.0 21,037.0 26.5 25.3 31.8 7.8
148.6 367,583.9 66,400.0 3,173.0 10.9 6.7 122.1 9.0
152.3 296,967.7 55,634.9 12,759.1 30.4 29.1 23.6 7.3
28.7 158,393.9 63,696.0 4,335.0 10.8 5 36.6 1.9
18.0 57,898.2 4,660,556.2 182,139.2 12.7 2.4 -- 1.2

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Teva Pharma Industries Ltd ADR (TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various...  dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel. 

  • Executive VP & CFO

    Mr. Eliyahu Sharon Kalif

  • President, CEO & Director

    Mr. Richard D. Francis

  • Headquarters

    Tel Aviv-Yafo

  • Website

    https://www.tevapharm.com

FAQs for Teva Pharma Industries Ltd ADR (TEVA)

The share price of Teva Pharma Industries Ltd ADR (TEVA) is $36.07 (NYSE) as of 31-Aug-2026 15:44 EDT. Teva Pharma Industries Ltd ADR (TEVA) has given a return of 54.97% in the last 3 years.

The P/E ratio of Teva Pharma Industries Ltd ADR (TEVA) is 62.39 times as on 21-Aug-2026, a 67 premium to its peers’ median range of 37.32 times.
The P/B ratio of Teva Pharma Industries Ltd ADR (TEVA) is 5.63 times as on 21-Aug-2026, a 27 discount to its peers’ median range of 7.75 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
25.96
4.63
2024
-15.24
4.65
2023
-21.23
1.58
2022
-4.14
1.30
2021
21.19
0.86

The 52-week high and low of Teva Pharma Industries Ltd ADR (TEVA) are Rs 38.37 and Rs 18.14 as of 01-Sep-2026.

Teva Pharma Industries Ltd ADR (TEVA) has a market capitalisation of $ 42,895 Mln as on 21-Aug-2026. As per SEBI classification, it is a Mid Cap company.

Before investing in Teva Pharma Industries Ltd ADR (TEVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.

loading...
loading...